NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression
Cancer cells respond differently to inhibitors of Poly (ADP-ribose) polymerase. Here the authors reveal that ovarian cancer cells with higher cellular NADP+ levels are more sensitive to clinically relevant PARP1 inhibitors and show that NADP+ act as an endogenous inhibitor of PARP enzymes.
Guardado en:
Autores principales: | Chunjing Bian, Chao Zhang, Tao Luo, Aditi Vyas, Shih-Hsun Chen, Chao Liu, Muzaffer Ahmad Kassab, Ying Yang, Mei Kong, Xiaochun Yu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5bbffa525898454999e7e01354382c95 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
PARP2 mediates branched poly ADP-ribosylation in response to DNA damage
por: Qian Chen, et al.
Publicado: (2018) -
Serine-linked PARP1 auto-modification controls PARP inhibitor response
por: Evgeniia Prokhorova, et al.
Publicado: (2021) -
In vitro analysis of PARP inhibitor nanoformulations
por: Baldwin P, et al.
Publicado: (2018) -
The metabolites NADP+ and NADPH are the targets of the circadian protein Nocturnin (Curled)
por: Michael A. Estrella, et al.
Publicado: (2019) -
PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
por: Amelia Barcellini, et al.
Publicado: (2021)